Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma (NHL), and some cases are resistant to first-line rituximab (RTX) treatment, leading to poor prognosis. Our previous research found that phosphorylated cylindromatosis (CYLD) is a target regulating apoptosis in RTX-resistant DLBCL.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
